A recent Medscape article contained good news for the 1.3 billion people affected by migraines worldwide; the FDA just approved the first intravenous drug to prevent them. Lundbeck’s Vyepti is a humanized monoclonal antibody that is taken once every 3 months in either 100 or 300 mg doses. Its approval was based on the results of two Phase III clinical studies that focused on both episodic and chronic migraines. Lundbeck expects the drug to be available in early April.
Quick Hits: FDA Clears New Migraine Prevention Drug
The intravenous medication is taken every 3 months to prevent migraines.
Feb 26, 2020
Recommended
Recommended
FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
Medical Device Innovations Report
Cutting-edge packaging technologies are transforming the medical device sector in PMMI’s “Innovation in Medical Device” report, featuring advanced materials, smart solutions, and evolving regulations. Editors share insights from nearly 300 PACK EXPO booth visits—each product deemed new and truly innovative—alongside video demonstrations of the equipment and materials on display.
Learn More
